• FY3/27 expected to be a transitional year – AS ONE delivered full year operating profit growth ahead of revenue growth in FY3/26, demonstrating the operating leverage in its model. The FY3/27 financial guidance points to a year of growth investments, which should translate to profitability improvement in future years. We note that AS ONE has maintained a strong track record of cost discipline, which makes us believe the elevated SG&A spend in FY3/27 is expected to generate meaningful returns. Further, top line growth outlook is positive and shows signs of increasing wallet share. Although ROE reached a record 13.3% and exceeded the FY3/28 MTP target ahead of schedule, we believe AS ONE will continue to incrementally improve its ROE and ROA.
28 May 2026
AS ONE (7476) Q4 FY3/26 results update: Setting conservative expectations for FY3/27
AS ONE Corporation (7476:TKS), 0 | MEDIPAL HOLDINGS Corporation (7459:TKS), 0 | Ship Healthcare Holdings, Inc. (3360:TKS), 0 | Suzuken Co., Ltd. (9987:TKS), 0 | TOHO HOLDINGS CO., LTD. (8129:TKS), 0 | Medius Holdings Co., Ltd. (3154:TKS), 0 | MonotaRO Co., Ltd. (3064:TKS), 0 | ASKUL Corporation (2678:TKS), 0 | Trusco Nakayama Corporation (9830:TKS), 0 | Thermo Fisher Scientific Inc. (TMO:NYS), 0 | Avantor, Inc. (AVTR:NYS), 0 | Sartorius AG (SRT:ETR), 0 | Bruker Corporation (BRKR:NAS), 0 | Bunzl plc (BNZL:LON), 2,360 | W.W. Grainger, Inc. (GWW:NYS), 0 | MSC Industrial Direct Co (MSM:NYSE), 0 | Genuine Parts Company (GPC:NYSE), 0 | CDW Corporation (CDW:NAS), 0
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
AS ONE (7476) Q4 FY3/26 results update: Setting conservative expectations for FY3/27
AS ONE Corporation (7476:TKS), 0 | MEDIPAL HOLDINGS Corporation (7459:TKS), 0 | Ship Healthcare Holdings, Inc. (3360:TKS), 0 | Suzuken Co., Ltd. (9987:TKS), 0 | TOHO HOLDINGS CO., LTD. (8129:TKS), 0 | Medius Holdings Co., Ltd. (3154:TKS), 0 | MonotaRO Co., Ltd. (3064:TKS), 0 | ASKUL Corporation (2678:TKS), 0 | Trusco Nakayama Corporation (9830:TKS), 0 | Thermo Fisher Scientific Inc. (TMO:NYS), 0 | Avantor, Inc. (AVTR:NYS), 0 | Sartorius AG (SRT:ETR), 0 | Bruker Corporation (BRKR:NAS), 0 | Bunzl plc (BNZL:LON), 2,360 | W.W. Grainger, Inc. (GWW:NYS), 0 | MSC Industrial Direct Co (MSM:NYSE), 0 | Genuine Parts Company (GPC:NYSE), 0 | CDW Corporation (CDW:NAS), 0
- Published:
28 May 2026 - Author:
-
Pages:
13 -
• FY3/27 expected to be a transitional year – AS ONE delivered full year operating profit growth ahead of revenue growth in FY3/26, demonstrating the operating leverage in its model. The FY3/27 financial guidance points to a year of growth investments, which should translate to profitability improvement in future years. We note that AS ONE has maintained a strong track record of cost discipline, which makes us believe the elevated SG&A spend in FY3/27 is expected to generate meaningful returns. Further, top line growth outlook is positive and shows signs of increasing wallet share. Although ROE reached a record 13.3% and exceeded the FY3/28 MTP target ahead of schedule, we believe AS ONE will continue to incrementally improve its ROE and ROA.